SSRIs treatment did not completely restore affective state in patients with the initial clinically confirmed major depressive disorder/generalized anxiety disorder after COVID-19 disease

IntroductionThe major clinical outcomes of COVID-19 in the brain are associated with its deleterious neurological and mental health actions.Today, there are limited findings concerning the studying of neuropsychiatric action for SARS-Cov-2 in humans after COVID-19 disease.ObjectivesThe aim of the pr...

Full description

Saved in:
Bibliographic Details
Published in:European psychiatry 2022-06, Vol.65 (S1), p.S96-S96
Main Authors: Fedotova, J., Bereza, Z.
Format: Article
Language:English
Subjects:
Abstract
anxiety
Coronaviruses
COVID-19
depression
Generalized anxiety disorder
Mental depression
Oral Communication
pharmacotherapy
Severe acute respiratory syndrome coronavirus 2
SSRIs
Women
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page S96
container_issue S1
container_start_page S96
container_title European psychiatry
container_volume 65
creator Fedotova, J.
Bereza, Z.
description IntroductionThe major clinical outcomes of COVID-19 in the brain are associated with its deleterious neurological and mental health actions.Today, there are limited findings concerning the studying of neuropsychiatric action for SARS-Cov-2 in humans after COVID-19 disease.ObjectivesThe aim of the present study was to compare the efficacy of SSRIs (escitalopram, sertraline and fluoxetine) for 6 months therapy on the affective profile of man and women with the clinically confirmed Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD) cases following COVID-19 disease.Methods. For the assessment of affective profile in man and women (30-55 years) with the initial clinically confirmed MDD or GAD cases after COVID-19 disease, we used the different tests: Montgomery-Asberg Depression Rating Scale (MADRS) and anxiety scale (ShARS Scale). The hormonal and monoamines levels in the serum blood were measured by ELISA tests before and after SSRIs therapy.ResultsAfter 6 months of SSRIs therapy, MADRS Scale showed a incomplete disappearance of the depressive/anxiety manifestations in both men and women with the initial clinically confirmed MDD case after COVID-19 (p
doi_str_mv 10.1192/j.eurpsy.2022.279
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_02e66da77abe43b6bab5ca2344638a08</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_02e66da77abe43b6bab5ca2344638a08</doaj_id><sourcerecordid>2708707229</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2349-b07f5a9c854e6795747547fd8cfd15055f959995884d97a898e4e6ed755a8ae33</originalsourceid><addsrcrecordid>eNpVks1q3DAQx01podu0D9CboGdvZNmypEuhbL8WAoGm7VWMpfGujNdyJW3S7aP16SJnQyAXScz85zcfmqJ4X9F1VSl2OazxGOZ4WjPK2JoJ9aJYVULIsuaSvyxWVLGmVHUtXxdvYhworQSl7ar4f3PzYxtJCgjpgFMi1lky-USMP8wjJhxPJGBMPiCBvkeT3C2SmCAhcROZIbkcFcmdS3uS9ovRJQcjMWN-GRhzvPFT78IBLTnA4AOxOGdkXEDWRR8shssdThhgdP-yCqa_DtPpyZkTp3xurn9vP5eVWuwIEd8Wr3oYI757vC-KX1-__Nx8L6-uv203n65Kw-pGlR0VPQdlJG-wFYqLRvBG9Faa3lacct4rrpTiUjZWCZBKYhaiFZyDBKzri2J75loPg56DO0A4aQ9OPxh82GkIyZkRNWXYthaEgA6bums76LiBXEbT1hKozKyPZ9Z87PJATJ5d7voZ9Llncnu987da8bbNNWbAh0dA8H-O-WP04I9hyv1rJqgUVDCmsqo6q0zwMQbsnzJUVC_7ogd93he97EsOVfU9_4y7OA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2708707229</pqid></control><display><type>article</type><title>SSRIs treatment did not completely restore affective state in patients with the initial clinically confirmed major depressive disorder/generalized anxiety disorder after COVID-19 disease</title><source>NCBI_PubMed Central（免费）</source><source>Publicly Available Content Database</source><source>Cambridge University Press:Jisc Collections:Cambridge University Press Read and Publish Agreement 2021-24 (Reading list)</source><source>Coronavirus Research Database</source><creator>Fedotova, J. ; Bereza, Z.</creator><creatorcontrib>Fedotova, J. ; Bereza, Z.</creatorcontrib><description>IntroductionThe major clinical outcomes of COVID-19 in the brain are associated with its deleterious neurological and mental health actions.Today, there are limited findings concerning the studying of neuropsychiatric action for SARS-Cov-2 in humans after COVID-19 disease.ObjectivesThe aim of the present study was to compare the efficacy of SSRIs (escitalopram, sertraline and fluoxetine) for 6 months therapy on the affective profile of man and women with the clinically confirmed Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD) cases following COVID-19 disease.Methods. For the assessment of affective profile in man and women (30-55 years) with the initial clinically confirmed MDD or GAD cases after COVID-19 disease, we used the different tests: Montgomery-Asberg Depression Rating Scale (MADRS) and anxiety scale (ShARS Scale). The hormonal and monoamines levels in the serum blood were measured by ELISA tests before and after SSRIs therapy.ResultsAfter 6 months of SSRIs therapy, MADRS Scale showed a incomplete disappearance of the depressive/anxiety manifestations in both men and women with the initial clinically confirmed MDD case after COVID-19 (p&lt;0,05). We found that SSRIs were able to reduce depression/anxiety levels only on 20% in man or on 30% in women with the initial MDD case after COVID-19 before treatment.ConclusionsSSRIs treatmet alone failed to produce the decrease of depression/anxiety in the patients of both gender with the initial MDD or GAD diagnosis after COVID-19. The further randomized clinical trials involving new pharmacological therapies for psychiatric pations after COVID-19 disease are needed.DisclosureNo significant relationships.</description><identifier>ISSN: 0924-9338</identifier><identifier>EISSN: 1778-3585</identifier><identifier>DOI: 10.1192/j.eurpsy.2022.279</identifier><language>eng</language><publisher>Paris: Cambridge University Press</publisher><subject>Abstract ; anxiety ; Coronaviruses ; COVID-19 ; depression ; Generalized anxiety disorder ; Mental depression ; Oral Communication ; pharmacotherapy ; Severe acute respiratory syndrome coronavirus 2 ; SSRIs ; Women</subject><ispartof>European psychiatry, 2022-06, Vol.65 (S1), p.S96-S96</ispartof><rights>The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2022 2022 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2708707229/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2708707229?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,38493,43871,44566,53766,53768,74155,74869</link.rule.ids></links><search><creatorcontrib>Fedotova, J.</creatorcontrib><creatorcontrib>Bereza, Z.</creatorcontrib><title>SSRIs treatment did not completely restore affective state in patients with the initial clinically confirmed major depressive disorder/generalized anxiety disorder after COVID-19 disease</title><title>European psychiatry</title><description>IntroductionThe major clinical outcomes of COVID-19 in the brain are associated with its deleterious neurological and mental health actions.Today, there are limited findings concerning the studying of neuropsychiatric action for SARS-Cov-2 in humans after COVID-19 disease.ObjectivesThe aim of the present study was to compare the efficacy of SSRIs (escitalopram, sertraline and fluoxetine) for 6 months therapy on the affective profile of man and women with the clinically confirmed Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD) cases following COVID-19 disease.Methods. For the assessment of affective profile in man and women (30-55 years) with the initial clinically confirmed MDD or GAD cases after COVID-19 disease, we used the different tests: Montgomery-Asberg Depression Rating Scale (MADRS) and anxiety scale (ShARS Scale). The hormonal and monoamines levels in the serum blood were measured by ELISA tests before and after SSRIs therapy.ResultsAfter 6 months of SSRIs therapy, MADRS Scale showed a incomplete disappearance of the depressive/anxiety manifestations in both men and women with the initial clinically confirmed MDD case after COVID-19 (p&lt;0,05). We found that SSRIs were able to reduce depression/anxiety levels only on 20% in man or on 30% in women with the initial MDD case after COVID-19 before treatment.ConclusionsSSRIs treatmet alone failed to produce the decrease of depression/anxiety in the patients of both gender with the initial MDD or GAD diagnosis after COVID-19. The further randomized clinical trials involving new pharmacological therapies for psychiatric pations after COVID-19 disease are needed.DisclosureNo significant relationships.</description><subject>Abstract</subject><subject>anxiety</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>depression</subject><subject>Generalized anxiety disorder</subject><subject>Mental depression</subject><subject>Oral Communication</subject><subject>pharmacotherapy</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>SSRIs</subject><subject>Women</subject><issn>0924-9338</issn><issn>1778-3585</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpVks1q3DAQx01podu0D9CboGdvZNmypEuhbL8WAoGm7VWMpfGujNdyJW3S7aP16SJnQyAXScz85zcfmqJ4X9F1VSl2OazxGOZ4WjPK2JoJ9aJYVULIsuaSvyxWVLGmVHUtXxdvYhworQSl7ar4f3PzYxtJCgjpgFMi1lky-USMP8wjJhxPJGBMPiCBvkeT3C2SmCAhcROZIbkcFcmdS3uS9ovRJQcjMWN-GRhzvPFT78IBLTnA4AOxOGdkXEDWRR8shssdThhgdP-yCqa_DtPpyZkTp3xurn9vP5eVWuwIEd8Wr3oYI757vC-KX1-__Nx8L6-uv203n65Kw-pGlR0VPQdlJG-wFYqLRvBG9Faa3lacct4rrpTiUjZWCZBKYhaiFZyDBKzri2J75loPg56DO0A4aQ9OPxh82GkIyZkRNWXYthaEgA6bums76LiBXEbT1hKozKyPZ9Z87PJATJ5d7voZ9Llncnu987da8bbNNWbAh0dA8H-O-WP04I9hyv1rJqgUVDCmsqo6q0zwMQbsnzJUVC_7ogd93he97EsOVfU9_4y7OA</recordid><startdate>20220601</startdate><enddate>20220601</enddate><creator>Fedotova, J.</creator><creator>Bereza, Z.</creator><general>Cambridge University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7XB</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>M2M</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20220601</creationdate><title>SSRIs treatment did not completely restore affective state in patients with the initial clinically confirmed major depressive disorder/generalized anxiety disorder after COVID-19 disease</title><author>Fedotova, J. ; Bereza, Z.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2349-b07f5a9c854e6795747547fd8cfd15055f959995884d97a898e4e6ed755a8ae33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Abstract</topic><topic>anxiety</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>depression</topic><topic>Generalized anxiety disorder</topic><topic>Mental depression</topic><topic>Oral Communication</topic><topic>pharmacotherapy</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>SSRIs</topic><topic>Women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fedotova, J.</creatorcontrib><creatorcontrib>Bereza, Z.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Psychology Database (ProQuest)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>European psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fedotova, J.</au><au>Bereza, Z.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SSRIs treatment did not completely restore affective state in patients with the initial clinically confirmed major depressive disorder/generalized anxiety disorder after COVID-19 disease</atitle><jtitle>European psychiatry</jtitle><date>2022-06-01</date><risdate>2022</risdate><volume>65</volume><issue>S1</issue><spage>S96</spage><epage>S96</epage><pages>S96-S96</pages><issn>0924-9338</issn><eissn>1778-3585</eissn><abstract>IntroductionThe major clinical outcomes of COVID-19 in the brain are associated with its deleterious neurological and mental health actions.Today, there are limited findings concerning the studying of neuropsychiatric action for SARS-Cov-2 in humans after COVID-19 disease.ObjectivesThe aim of the present study was to compare the efficacy of SSRIs (escitalopram, sertraline and fluoxetine) for 6 months therapy on the affective profile of man and women with the clinically confirmed Major Depressive Disorder (MDD) or Generalized Anxiety Disorder (GAD) cases following COVID-19 disease.Methods. For the assessment of affective profile in man and women (30-55 years) with the initial clinically confirmed MDD or GAD cases after COVID-19 disease, we used the different tests: Montgomery-Asberg Depression Rating Scale (MADRS) and anxiety scale (ShARS Scale). The hormonal and monoamines levels in the serum blood were measured by ELISA tests before and after SSRIs therapy.ResultsAfter 6 months of SSRIs therapy, MADRS Scale showed a incomplete disappearance of the depressive/anxiety manifestations in both men and women with the initial clinically confirmed MDD case after COVID-19 (p&lt;0,05). We found that SSRIs were able to reduce depression/anxiety levels only on 20% in man or on 30% in women with the initial MDD case after COVID-19 before treatment.ConclusionsSSRIs treatmet alone failed to produce the decrease of depression/anxiety in the patients of both gender with the initial MDD or GAD diagnosis after COVID-19. The further randomized clinical trials involving new pharmacological therapies for psychiatric pations after COVID-19 disease are needed.DisclosureNo significant relationships.</abstract><cop>Paris</cop><pub>Cambridge University Press</pub><doi>10.1192/j.eurpsy.2022.279</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0924-9338
ispartof European psychiatry, 2022-06, Vol.65 (S1), p.S96-S96
issn 0924-9338
1778-3585
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_02e66da77abe43b6bab5ca2344638a08
source NCBI_PubMed Central（免费）; Publicly Available Content Database; Cambridge University Press:Jisc Collections:Cambridge University Press Read and Publish Agreement 2021-24 (Reading list); Coronavirus Research Database
subjects Abstract
anxiety
Coronaviruses
COVID-19
depression
Generalized anxiety disorder
Mental depression
Oral Communication
pharmacotherapy
Severe acute respiratory syndrome coronavirus 2
SSRIs
Women
title SSRIs treatment did not completely restore affective state in patients with the initial clinically confirmed major depressive disorder/generalized anxiety disorder after COVID-19 disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T04%3A56%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SSRIs%20treatment%20did%20not%20completely%20restore%20affective%20state%20in%20patients%20with%20the%20initial%20clinically%20confirmed%20major%20depressive%20disorder/generalized%20anxiety%20disorder%20after%20COVID-19%20disease&rft.jtitle=European%20psychiatry&rft.au=Fedotova,%20J.&rft.date=2022-06-01&rft.volume=65&rft.issue=S1&rft.spage=S96&rft.epage=S96&rft.pages=S96-S96&rft.issn=0924-9338&rft.eissn=1778-3585&rft_id=info:doi/10.1192/j.eurpsy.2022.279&rft_dat=%3Cproquest_doaj_%3E2708707229%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2349-b07f5a9c854e6795747547fd8cfd15055f959995884d97a898e4e6ed755a8ae33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2708707229&rft_id=info:pmid/&rfr_iscdi=true